Skip to main content
PMC home page
International Journal of Methods in Psychiatric Research logoLink to International Journal of Methods in Psychiatric Research
. 2006 Mar 24;12(3):117–127. doi: 10.1002/mpr.148

A comparison of antidepressant trials using active and inert placebos

Joanna Moncrieff 1,✉
PMCID: PMC6878450  PMID: 12953139

Abstract

In placebo‐controlled antidepressant trials, there are concerns that the double blind may be breached, which may bias results. Some trials have therefore used placebos containing active substances in order to mimic the side effects of antidepressants. This study set out to examine the impact of ‘unblinding’ by comparing the results of a meta‐analysis of a sample of trials using ordinary inert placebos with a meta‐analysis of trials using active placebos. An a priori sub‐group analysis of trials conducted with inpatients and outpatients was carried out. Quality was assessed using a quality assessment instrument and meta‐regression analysis was conducted to explore heterogeneity. Results of meta‐analysis did not differ between trials using active placebos and trials using inert ones. However, results were strongly influenced by two large trials. When these were excluded trials using inert placebos showed greater antidepressant‐placebo differences than trials using active placebos. There was very high heterogeneity especially among trials using inert placebos. Meta‐regression analysis showed the only significant predictor of outcome was whether trials were conducted with inpatients or outpatients. Sub‐group analysis showed significant differences between antidepressants and any type of placebo in trials conducted with outpatients but not in inpatient trials. Lack of data, heterogeneity and the influence of large studies limited the analysis. The integrity of the double blind design, its effect on results and the heterogeneity between studies, require further exploration in antidepressant trials. Copyright © 2003 Whurr Publishers Ltd.

Keywords: antidepressants, placebo, meta‐analysis, double blind

Full Text

The Full Text of this article is available as a PDF (92.2 KB).

References

  1. Abraham HC, Kanter VB, Rosen I, Standen JL. A controlled clinical trial of imipramine with out‐patients. British Journal of Psychiatry 1963; 109: 286–93. [DOI] [PubMed] [Google Scholar]
  2. Ainslie, JD , Jones MB, and Stiefel JR. Practical drug evaluation method. Archives of General Psychiatry 1965; 12: 368–73. [DOI] [PubMed] [Google Scholar]
  3. Anderson IM, Nutt DJ, Deakin JFW on behalf of the Consensus Meeting and endorsed by the British Association of Psychopharmacology. Evidence based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology Guidelines. Journal of Psychopharmacology 2000; 14: 3–20. [DOI] [PubMed] [Google Scholar]
  4. Angst J, Scheidegger P, Stabl M. Efficacy of moclobemide in different patient groups: results of new subscales of the Hamilton Rating Scale. Clinical Neuropharmacoloigy 1993; 16 (Suppl. 2): S55–S62. [PubMed] [Google Scholar]
  5. Bellack AS, Hersen M, Himmelhoch J. Social skills training compared with pharmacotherapy and psychotherapy in the treatment of unipolar depression. American Journal of Psychiatry 1981; 138: 1562–7. [DOI] [PubMed] [Google Scholar]
  6. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta‐analysis of dose‐effect relationships in randomised clinical trials. British Journal of Psychiatry 1999; 174: 297–303. [DOI] [PubMed] [Google Scholar]
  7. Brick H, Doub WHJ, Perdue WC. Effects of amitriptylene on depressive and anxiety states in penitentiary inmates. Diseases of the Nervous System 1962; 22: 572–8. [PubMed] [Google Scholar]
  8. Daneman EA. Imipramine in office management of depressive reactions. Diseases of the Nervous System 1961; 22: 213–17. [PubMed] [Google Scholar]
  9. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis In Egger M, Smith GD, Altman DG. (eds) Systematic Reviews in Health Care, second edition London: BMJ Publishing Group , 2001. [Google Scholar]
  10. Diamond S. Double‐blind controlled study of amitriptyleneperphenazine combination in medical office patients with depression and anxiety. Psychosomatics 1966; 7: 371–5. [Google Scholar]
  11. Elkin I, Shea T, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB National Institute of Mental Health treatment of depression collaborative research program. Archives of General Psychiatry 1989; 46: 971–82. [DOI] [PubMed] [Google Scholar]
  12. Engelhardt DM, Margolis RA, Rudorfer L, Paley HM. Physician bias and the double‐blind. Archives of General Psychiatry 1969; 20: 315–20. [DOI] [PubMed] [Google Scholar]
  13. Even C, Siobud‐Dorocant, Dardennes Critical approach to antidepressant trials. Blindness protection is necessary, feasible and measurable. British Journal of Psychiatry 2000; 177: 47–51. [DOI] [PubMed] [Google Scholar]
  14. Fink M, Klein DF, Kramer JC. Clinical efficacy of chlorpromazine‐procyclidine combination, imipramine and placebo in depressive disorders. Psychopharmacologia 1965; 7: 27–36. [PubMed] [Google Scholar]
  15. Friedman AS, Granick S, Cohen HW, Cowitz B. Imipramine (tofranil) vs placebo in hospitalized psychotic depressives. Journal of Psychiatric Research 1966; 4: 13–36. [DOI] [PubMed] [Google Scholar]
  16. Friedman AS. Interaction of drug therapy with marital therapy in depressive patients. Archives of General Psychiatry 1975; 32: 619–37. [DOI] [PubMed] [Google Scholar]
  17. Garry JW, Leonard T J. Trial of amitriptylene in chronic depression. British Journal of Psychiatry 1963; 109: 54–5. [DOI] [PubMed] [Google Scholar]
  18. Greenberg RP, Fisher S. Suspended judgement. Seeing through the double masked design: a commentary. Controlled Clinical Trials 1994; 15: 244–6. [DOI] [PubMed] [Google Scholar]
  19. Hall J, Lonie D. A controlled trial of amitriptylene for treatment of depression in inpatients. New Zealand Medical Journal 1962; 61: 548–50. [PubMed] [Google Scholar]
  20. Hamilton MA. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960; 23: 56–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta‐analysis. BMJ 1995; 310: 897–901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Holdway V. Trial of imipramine. Journal of Mental Science 1960; 106: 1443–6. [DOI] [PubMed] [Google Scholar]
  23. Hollister LE, Overall JE, Johnson M, Katz G, Kimbell I, Honigfeld G. Evaluation of desipramine in depressive states. Journal of New Drugs 1963; 3: 161–6. [DOI] [PubMed] [Google Scholar]
  24. Hollister LE, Overall JE, Johnson M, Pennington V, Katz G, Shelton J. Controlled comparison of imipramine, amitriptyline and placebo in hospitalised depressed patients. Journal of Nervous and Mental Disease 1964; 139: 370–5. [DOI] [PubMed] [Google Scholar]
  25. Hussain Z. Drugs in depressive illness. British Medical Journal 1970; I: 482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 2002; 22: 40–5. [DOI] [PubMed] [Google Scholar]
  27. Kirsch I The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention and Treatment, 2002; 5, available at http://journals.apa.org/prevention
  28. Kocsis JH, Croughan JL, Katz MM, Butler TP, Secunda C, Bowden CL, Davis JM. Response to treatment with antidepressants of patients with severe or moderate non psychotic depression and of patients with psychotic depression. Am J Psychiatry 1990; 147: 621–4. [DOI] [PubMed] [Google Scholar]
  29. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N. Placebo controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391–7. [DOI] [PubMed] [Google Scholar]
  30. Lorr M, Jenkins R, Holsopple J. Multidimensional scale for rating psychiatric patients. Veterans Administration Technical Bulletin. Washington: Veterans Association, 1953; 10–507. [Google Scholar]
  31. Master RS. Amitriptyline in depressive states. A controlled trial in India. British Journal of Psychiatry 1963; 109: 826–9. [DOI] [PubMed] [Google Scholar]
  32. McCallum P, Reares R. A controlled trial of mapriotiline in depressed out‐patients. Medical Journal of Australia 1975; 2: 392–3. [DOI] [PubMed] [Google Scholar]
  33. Moncrieff J, Churchill R, Drummond DC, McGuire H. Development of a quality assessment instrument for trials of treatments of depression and neurosis. International Journal of Methods in Psychiatric Research 2001b; 10: 126–33. [Google Scholar]
  34. Moncrieff J, Wessely S, Hardy R. Meta‐analysis of trials comparing antidepressants with active placebos. British Journal of Psychiatry 1998; 172: 227–31. [DOI] [PubMed] [Google Scholar]
  35. Moncrieff J, Wessely S, Hardy R. Antidepressants versus active placebos. Cochrane Database of Systematic Reviews, 2001a. [DOI] [PubMed]
  36. Morris JB, Beck AT. The efficacy of antidepressant drugs. A review of research (1958 to 1972). Archives of General Psychiatry 1974; 30: 667–74. [DOI] [PubMed] [Google Scholar]
  37. Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy. Archives of General Psychiatry 1984; 41: 33–41. [DOI] [PubMed] [Google Scholar]
  38. Ottervanger EA The efficacy of fluvoxamine in patients with severe depression. British Journal of Clinical Research 1991; 2: 125–32. [Google Scholar]
  39. Overall JE. Dimensions of manifest depression. Journal of Psychiatric Research, 1962; 1: 239–248. [Google Scholar]
  40. Paykell ES Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo controlled trial. Journal of Affective Disorders 1988; 14: 83–95. [DOI] [PubMed] [Google Scholar]
  41. Porter AMW. Depressive illness in a general practice. A demographic study and a controlled trial of imipramine. BMJ 1970; 1: 773–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Prange AJ, McCurdy RL, Cochrane CM. The systolic blood pressure response of depressed patients to infused norepinephrine. Journal of Psychiatric Research 1967; 5: 1–13. [DOI] [PubMed] [Google Scholar]
  43. Quality Assurance Project . A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry 1983; 17: 129–46. [DOI] [PubMed] [Google Scholar]
  44. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. American Journal of Psychiatry 2000; 157: 327–37. [DOI] [PubMed] [Google Scholar]
  45. Raskin A, Crook TH. Antidepressants in black and white inpatients. Archives of General Psychiatry 1975; 32: 643–9. [DOI] [PubMed] [Google Scholar]
  46. Raskin A, Schulterbrandt JG, Reatig N, Chase C, McKeon JJ. Differential response to chlorpromazine, imipramine and placebo. Archives of General Psychiatry 1970; 23: 164–73. [DOI] [PubMed] [Google Scholar]
  47. Rickels K, Ward CH, Schut L. Different populations, different responses. A comparative study of two antidepressants each used in two different patient groups . American Journal of Medical Science 1964; 47: 328–35. [DOI] [PubMed] [Google Scholar]
  48. Smith RC. Amoxapine, imipramine and placebo in depressive illness. Current Therapeutic Research 1975; 18: 346–53. [PubMed] [Google Scholar]
  49. Stata 7. Texas, USA: Stata Corporation, 2002. [Google Scholar]
  50. Thompson S. Why and how sources of heterogeneity should be investigated In Egger M, Smith GD, Altman DG. (eds) Systematic Reviews in Healthcare. London: BMJ Publishing Group , 2001. [Google Scholar]
  51. Toneatto T, Sellers EM. Perception of whether drug or placebo has been administered is a determinant of drinking reduction In Sellers EM. and Naranjo CA. (eds) Novel Pharmacological Interventions for Alcoholism. California: Springer Verlag; 1992. [Google Scholar]
  52. Uhlenhuth EH, Park LC. The influence of medication (imipramine) and doctor in relieving depressed psychoneurotic outpatients. Journal of Psychiatric research 1963; 2: 101–22. [DOI] [PubMed] [Google Scholar]
  53. Weintraub W, Aronson H. clinical judgment in psychopharmacological research. Journal of Neuropsychiatry 1963; 5: 65–70. [PubMed] [Google Scholar]
  54. White K, Kando J, Park T, Waternaux C, Brown WA. Side effects and the ‘blindability’ of clinical drug trials. American Journal of Psychiatry 1992; 149: 1730–61. [DOI] [PubMed] [Google Scholar]
  55. Wilson IC, Vernon JT, Guin T, Sandifer MG. A controlled study of treatments of depression. Journal of Neuropsychiatry 1963; 4: 331–7. [PubMed] [Google Scholar]

Articles from International Journal of Methods in Psychiatric Research are provided here courtesy of Wiley

RESOURCES